
Lupin Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company targets steady growth aiming for $5 billion revenue in 3-5 years (Page 18).
- US business expected to ramp up to around $250 million per quarter by FY26, driven by new product launches including Tolvaptan, Liraglutide (subject to approval), and ophthalmic injectables (Pages 15, 16).
- Tiotropium (Spiriva) market share projected to ramp from 25% towards 35-40% within a year, with stable pricing expected (Pages 7-9).
- India business plans to outperform the market with mid to long-term growth better than high single digits, gaining from new introductions and volume increases (Pages 11-12).
- Strong growth expected from complex generics, injectables, inhalers, and ophthalmics, with multiple filings and launches lined up especially in FY25 and FY26 (Pages 11-14).
- Europe and other non-US markets also showing robust sales growth and capacity expansions planned to support launches in multiple regions (Page 9).
See what Lupin management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Lupin management said on order book — free account, 30 seconds.
Capex plans
YesTrack Lupin — get its next earnings analysis in your feed
How does Lupin rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Lupin rank in Pharmaceuticals & Biotechnology?
Compare Lupin against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Lupin's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem